Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update
GastroenterologiaSobre o estudo
- Desenho
- Revisão sistemática
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Publicado em
- 22 dez 2021
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update
Nancy N Baxter, Erin B Kennedy, Emily K Bergsland, Jordan Berlin, Thomas J George, Sharlene Gill, Philip J Gold, Alex Hantel, Lee Jones, Christopher Lieu et al.
Descritores MeSH
- Colonic Neoplasms
- Microsatellite Instability
- Brain Neoplasms
- Leucovorin
- Fluorouracil
- Oxaliplatin
- Neoplasm Staging
- Neoplastic Syndromes, Hereditary
- Colorectal Neoplasms
- Chemotherapy, Adjuvant
Veja também
Estudos relacionados
- Optimal duration of oxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer: a meta-analysis
- Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial
- Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial
- Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial
- The prognostic value of tumour budding for survival in stage II and III colorectal cancer: a systematic review and meta-analysis